Brief: Quantum Genomics H1 Operating Loss Widens To 6.8 Million Euros

Quantum Genomics SA

04/10/2018 17:13

Oct 4 (Reuters) - QUANTUM GENOMICS SA  ALQGC.PA :
    * QUANTUM GENOMICS REPORTS FIRST HALF FINANCIAL RESULTS
    * RECRUITMENT COMPLETED MORE THAN SIX MONTHS AHEAD OF
SCHEDULE FOR
PHASE 2B NEW-HOPE TRIAL OF FIRIBASTAT FOR TREATMENT OF
HYPERTENSION IN THE UNITED STATES
    * H1 NET LOSS EUR 6.2 MILLION VERSUS LOSS EUR 4.0 MILLION
YEAR AGO
    * ANNOUNCED DESIGN OF PHASE 2B QUORUM TRIAL OF FIRIBASTAT
FOR
TREATMENT OF HEART FAILURE
    * NEW GOVERNANCE INTRODUCED TO DRIVE DEVELOPMENT OF BRAIN
AMINOPEPTIDASE A INHIBITORS (BAPAIS)
    * H1 OPERATING LOSS EUR 6.8 MILLION VERSUS LOSS EUR 4.5
MILLION
YEAR AGO
    * AVAILABLE CASH FLOW AT END H1 WAS €6.0 MILLION, COMPARED
WITH
€11.1 MILLION AT DECEMBER 31, 2017
    * APPROVAL OF THE GENERIC NAME 'FIRIBASTAT' BY THE WORLD
HEALTH
ORGANIZATION 

Source text for Eikon:  ID:nNDL20y8LD 
Further company coverage:  ALQGC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))